Interim Report Second Quarter 2019
STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2019 – 30.06.2019. The report is available as an attached file and on www.stenocare.dk/investor/EN.Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “The medical cannabis industry is young and defined by almost limitless demand and varying degrees of turbulence. Referring to our press release earlier this morning regarding additional cultivation related issues identified at CannTrust, we are now in a new situation regarding the STENOCARE products from CannTrust and will work with the Danish Medicines